ArticleBMC cancer2026
Oxaliplatin induced peripheral neuropathy and associated factors among colorectal cancer patients in Tanzania.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the leading malignancies globally and chemotherapy forms the bulk of its management. Oxaliplatin is one of the standard drugs used for management of colorectal cancer. Oxaliplatin induced peripheral neuropathy (OIPN) is one of the most debilitating toxicities encountered which can lead to dose modification and premature treatment discontinuation with a great impact on quality of life. Therefore, we aimed to determine the prevalence, severity and factors associated with OIPN among colorectal cancer patients treated in Tanzania.
methodsThis retrospective cohort study conducted at Ocean Road Cancer Institute (ORCI) of histologically confirmed CRC patients who were on oxaliplatin-based chemotherapy regimens. Data was collected using EORT-QLQ CIPN20 questionnaire and analysis was done using SPSS version 23 and p value < 0.05 was considered statistically significant.
resultsA total of 62 patients were recruited, the prevalence of OIPN was 71% and 59.7% for acute and chronic symptoms respectively. Obese patients were 21.66 times higher at risk of suffering from chronic OIPN compared to individuals who have normal body weight (p < 0.05). Cumulative Dose ≤ 780 showed a protective effect (p < 0.005) in development of OIPN. For the severity of acute OIPN, it was found that 4.8% had grade 4 symptoms, while 8.1% had grade 3 symptoms, and 69.4% had grade 2 symptoms, and 17.7% of the patients had grade 1. In patients with chronic OIPN, 13.5% had grade 3 neuropathies, 24.3% had grade 2 and 62.2% had grade 1 neuropathy.
conclusionThe prevalence of acute and chronic OIPN among colorectal cancer patients managed at ORCI was 71.0% and 59.7% respectively, with most patients developing grade 1 and 2 neuropathy for both acute and chronic symptoms. Number of cycles, cumulative dose and BMI were the major factors associated with the neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.